Los Angeles is expected to roll out COVID-19 test kiosks later this month. A similar program in Berkeley may offer a hint of what it will look like.
Curative Inc. the company that administers COVID-19 tests, started a kiosk pilot program in Berkeley that opened last month.
Located in a park in Berkeley, the self-administered testing sites allow individuals to swab their own mouths and place samples in a supervised receptacle. The purple booth with the company's emblem reads "Welcome to your test spot." and "We're glad you are here."
Fred Turner, co-founder of Curative, tweeted out the photos of those kiosk less than a week before Mayor Eric Garcetti announced a similar program on Wednesday.
The kiosks in Los Angeles will process about 500 tests a day and are an alternative to the city's drive-thrus, which can be difficult for residents without cars to get to, Garcetti said.
Great to see our first @Curative mobile COVID-19 testing kiosk in action in @CityofBerkeley this week! We are hopin… https://t.co/yXBL0zOTuY— Fred Turner (@Fred Turner)1596141719.0
"We think this will be a great way of getting tests to people that can't necessarily use one of the drive thrus and making testing more of a part of our daily lives as we continue to fight this pandemic," Turner said during a press conference with L.A. Mayor Eric Garcetti.
The company is also rolling out a mobile unit that's being deployed to hot spots around Los Angeles. Garcetti said the city wants to be able to bring these to people in need.
"We are just getting to the point where it's getting a lot easier to get tested, but it's going to continue to be a pressing need to offer tests and for anybody who wants a test to be able to get tested," Turner said.
Curative has administered 1 million tests in Los Angeles and is averaging about 18,000 a day with an eye toward growing its capacity further.
Watch the full press announcement below:
COVID-19 Response Update from Mayor Garcetti, August 5, 2020
Join me live at a COVID-19 testing site for the latest on testing and more updates on our work to slow the spread of the virus.
From Your Site Articles
- curative-inc - dot.LA ›
- Here's How Curative, Inc, Plans to Roll Out Coronavirus Testing to ... ›
- Watch: Curative Sends 240K COVID-19 Tests to Texas as Infections ... ›
- Your Next COVID Test Could Come From a Vending Machine - dot.LA ›
- Curative Founder Fred Turner on Next Steps For COVID Testing ... ›
Related Articles Around the Web
A $5 million rapid COVID-19 testing competition launched Tuesday by the Culver-City based XPRIZE Competition seeks to make tests cheaper and faster.
Long wait times for test results have hampered efforts across the country to contain coronavirus. As labs have fallen behind in some parts of the country, wait times have stretched into days and even weeks — and that's meant potentially infectious patients who haven't yet gotten their results aren't self-isolating.
<p>"Fast, affordable, and accessible testing is crucial to containing the COVID-19 pandemic and safely reopening schools, businesses and other vital institutions around the world," said CEO of XPRIZE, Anousheh Ansari in announcing the competition. "XPRIZE Rapid COVID Testing is inspiring the best entrepreneurial and scientific teams to come together to work towards rapid, affordable COVID-19 testing at scale, and ultimately, getting the world up and running again."</p><p>XPRIZE is partnering with OpenCovidScreen to spur production of a low-cost, easy-to-use and fast-result test. The organization hopes it will allow more people to be tested, and bring them closer to safely returning to their jobs and schools.</p><p>The competition encourages high school students, university groups, innovators and startups to form teams and work on a solution for the lack of testing capacity. It allows contestants to enter into one of four different categories such as: At Home, Point-of-Care, Distributed Lab, or High-Throughput Lab.</p><p>Teams have until August 31st to enter the competition and just 6 months to develop the test with certain requirements. The test must have a maximum turnaround time of 12 hours and cannot cost more than $15.</p><p>Blue Shield of California, Cambia Health Solutions, Health Care Service Corporation, GuideWell Mutual Holding Corporation, Horizon Healthcare Services, BlueCross BlueShield of South Carolina, The Anthem Foundation and Anthem Inc. are among the companies backing the effort.</p><p>And companies including Google, Amazon, Ilumina, Ancestry, Thermo Fisher Scientific, Exact Science, Centerview Partners, Twist Bioscience,<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fopentrons.com%2F&esheet=52256756&newsitemid=20200728005380&lan=en-US&anchor=Opentrons%2C&index=18&md5=f521ea72a1df0ff5dabf659cd33494c8" target="_blank"> Opentrons, </a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhudsonalpha.org%2F&esheet=52256756&newsitemid=20200728005380&lan=en-US&anchor=HudsonAlpha+Institute+for+Biotechnology&index=19&md5=1f697543a8c6bca26a5bd7df6b91b16b" target="_blank">HudsonAlpha Institute for Biotechnology</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.testingforamerica.org%2F&esheet=52256756&newsitemid=20200728005380&lan=en-US&anchor=Testing+For+America&index=20&md5=ec48d7459b6c8ac2b0a0d14d3e5c70d5" target="_blank">Testing For America</a> will help support contestants' need for technology and labs.</p><p>Five winners will share $5 million and can go on to benefit from The Covid Apollo Project's $50 million fund that aims to bring new testing methods to the market. </p>
Read more
Show less
Here's How Biotech Company Quantgene Plans to Extend Human Life by 10 Years Within a Decade
Jul 22 2020
Jo Bhakdi thinks he can extend life with data.
Over the past years, the trained economist and co-founder of Quantgene has helped create a blood test that screens for early signs of some of the deadliest cancers, using millions of culled data points.
"We have a bigger vision behind this," Bhakdi said. "It's what I call decades in a decade — to extend the average human lifespan by ten years in the next ten years."
<p>Quantgene has been developing so-called "liquid test" that can pinpoint the origin of multiple types of cancer by identifying their cellular mutations using artificial intelligence analytics and big data.</p><p>The project began five years ago at a U.C. Berkeley lab. Bhakdi partnered with co-founder Monika Hagen to create a system that would screen cancer using algorithms. </p><p>Late this year, Bhakdi and Hagen expect to roll out an early cancer screening subscription plan to consumers for an annual cost of around $2,200, pending regulatory approval. And they specifically came to Los Angeles, an image-conscious city that's embraced the idea of wellness, to launch it. </p><p>Blood tests are not a new technology for cancer screening, but Quantgene and others are trying to create a more precise tool to identify cancer in its earliest stages by finding mutation patterns that point to the disease. And in the process lower cancer death rates in the U.S.. This year, an estimated 600,000 people will die of the disease. Another 1.6 million will get the grim diagnosis. It's the second biggest killer of Americans year in and year out.<br/></p><p>Most blood tests are currently used when doctors already know where the cancer exists, mostly in order to track its progression.</p>
<img lazy-loadable="true" src="https://assets.rebelmouse.io/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yMzUwMzQ2MC9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTYwMTMzNjgyMn0.7aUvm0xnqnrEvQQLudaFjOL8gm8ZEwiFlw307vneCos/img.jpg?width=980" id="2e965" class="rm-shortcode" data-rm-shortcode-id="3df87781d62101223bf143a5460f78f8" data-rm-shortcode-name="rebelmouse-image" />Quantgene founders Jo Bhakdi and Monika Hagen
<p>The new tests examine fragments of DNA that break loose in the bloodstream. Quantgene looks at the different mutations of these cells to identify patterns that signal early forms of cancer or other diseases. The company plans to sell the system as part of a line of tiered-price testing called "Serenity" that includes genetic counseling and profiles.</p><p>Quantgene is branding the complex sequencing and AI process that analyzes these mutations the "Griffin Deep Genomics Platform." The company has raised more than $13 million, and expects to raise a Series B round this fall. Bhakdi believes it could upend how people test for cancer. But it has competition.</p><p>Amazon-backed, Menlo Park-based Grail Inc. has raised nearly $2 billion. In March, the Silicon Valley company released a report that said it could detect 50 types of cancer across all stages, with a false-positive rate below 1%. The company said it can find its location with 93% accuracy. But finding early-stage cancer — the type that actually save lives — has proven elusive.</p>
<p>Of the 12 deadly cancer types that make up 63% of deaths in the U.S., Grail reported a detection rate of 67% for stages one to three. The company's test is expected to be available within 12 months. A spokeswoman said in an email, it's "too early to comment on cost, however, our principal goal is to ensure broad access to our test, and we hope to make this ground breaking technology available to as many people as possible." Investors include Bill Gates, Bristol-Myers Squibb and Merck.</p><p>"The problem with a lot of these liquid biopsy technologies right now — Grail and others — is that they are not really good at detecting cancers at the earliest stages. Because there just isn't that much tumor material in the blood," said Timothy Rebbeck, director of the Zhu Family Center for Global Cancer Prevention at Harvard. "So, it's not to say that it couldn't be done. It's just the right now the technology is not refined enough to do it that really well."</p><h3>Getting to Cancer Screening at Earlier Stages</h3><p>For the last few decades, physicians have screened individual organs for signs of cancer, trying to suss out whether a patient has a cancerous growth on the pancreas or breast or lung. These early screenings, coupled with advances in cancer treatments, have been credited with a decline in U.S. deaths related to cancer. </p><p>"The median point of diagnosis in these 1.6 million is between stage three and stage four.</p><p>If you can shift that point of stage two and one, you would be saving 400,000 people a year," <strong></strong>Bhakdi said. "That's crazy if you think about that."</p><p>Bhakdi, who comes from a family of scientists and doctors, began the search less than a month before his own mother was diagnosed with stage four colon cancer. </p><p>At the time, a family member asked his help in solving a genomic question about whether one could determine if a random, isolated cell was cancer. The answer is very difficult to get. It lays in sequencing the cell's DNA and then comparing it to thousands of others. That ability to compare cells with a massive data trove is now at the heart of their company.</p><p class="shortcode-media shortcode-media-rebelmouse-image">
<img type="lazy-image" data-runner-src="https://dot.la/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yMzUwMzUwMy9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTYxNzkwOTE2NX0.LChIQNAUI5exZRIAq20luDZAhCOtzH-7vFlTxwe-29k/image.jpg?width=980" id="945c5" class="rm-shortcode" data-rm-shortcode-id="74b845f551c12bea72d1019eaa696fc1" data-rm-shortcode-name="rebelmouse-image" />
<small class="image-media media-caption" placeholder="Add Photo Caption...">A flow cell used for deep-sequencing produces 6 billion data points per patient sample.</small><small class="image-media media-photo-credit" placeholder="Add Photo Credit...">Courtesy Quantgene</small></p><p>Bhakdi believes it would have saved his mother.<br/></p><p>"If you are diagnosed with colon cancer at stage one, you have a 94% survival rate," he said. "In stage four, you have an 11% survival rate."</p><h3>Sidestepping Insurers in Santa Monica</h3><p>One of the best ways to bring down deaths is to diagnose cancer early, said Rebbeck. But even when these technologies are developed for widespread use they could exacerbate disparities for the poor, underserved and uninsured. That's because there remains systemic hurdles of access and cost.</p><p>Bhakdi said he understands those concerns. He had hoped originally to work with insurers to get the product out, but they required long-term economic studies to prove they would lower costs. Unable to produce that quickly, Quantgene moved to Santa Monica last year. </p><p>"We asked the question, 'What region has the most innovation-driven and future-oriented consumers and physicians and health care experts that are most likely to adopt new technologies?'," he said. "And what we found was very clear, very clear: Los Angeles."</p><p>In short, people in Los Angeles pay well to be healthy and beautiful. He pointed to companies that thrive in the metropolis like Next Health, a self-described longevity center that offers cryotherapy, or Remedy Place, a social wellness club.</p><p>"There's a big population here, a lot of whom are focused on health and wellness and are willing to spend the money," said David Whelan, chief executive of BioScienceLA, "The Goop effect sort of worked here. This is the place to be able to get a lot of customers very quickly when you're charging a high price point for customized service."</p><p>Beyond that, Bhakdi said there's also an extreme level of excellence in clinical infrastructure from medical institutions at UCLA, USC, City of Hope and Cedars-Sinai.</p><p>The move, he said, will hopefully allow Quantgene to demonstrate the product's value and convince insurers to offer it, eventually getting it into more people's hands. At the same time, the cost should draw down. </p><p>By 2024, the marketplace for personalized medicine and testing is expected to hit $85 billion, according to Pitchbook. </p><h3>How does it work?</h3><p>The company uses what's called cell-free DNA in the bloodstream to look for somatic mutations, those that are unrelated to hereditary factors and indicate a cancer growth. </p><p>"It's not a black and white thing," Bhakdi said. </p><p>It's more like matching different cancer profiles via machine learning. Using algorithms, the company traces the mutation patterns and compares those patterns to others who have the disease. By comparing the patient's mutation pattern along with their profile, Quantgene determines whether a specific cancer is maturing and tries to spot it.<span></span></p><p>"What the report does is not tell you whether you have cancer or not. That would be irresponsible," Bhakdi said. "It looks into the mutation pattern of the DNA that is in your gut — which means all the DNA that comes from, say, the diet in your body — and it takes these patterns and gives you a very high-resolution insight into how this compares with people with... all other kinds of medical conditions, including the ten leading cancers."</p><p>In 2016, Quantgene launched a clinical trial that will help them determine the sensitivity and specificity of the tests. Their goal is to have 10,000 patient blood samples. So far the company has about 5,000.<br/></p><p class="shortcode-media shortcode-media-rebelmouse-image">
<img type="lazy-image" data-runner-src="https://dot.la/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yMzUwMzUwNC9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTYzMTY5MTU1NH0.yzCqnaLxbeH1UsJpAUGuKPfl4GkGME8tiH4z36oy9kQ/image.jpg?width=980" id="e2627" class="rm-shortcode" data-rm-shortcode-id="baa66650927d58e940f222e10f3fbb69" data-rm-shortcode-name="rebelmouse-image" alt="quantgene" />
<small class="image-media media-caption" placeholder="Add Photo Caption...">Quantgene has developed a custom assay for DNA extraction</small><small class="image-media media-photo-credit" placeholder="Add Photo Credit...">Courtesy of Quantgene</small></p><p>But those working with the company think once it comes to market, it could be a game changer, helping physicians figure out how to deal with early signs of cancer.</p><p>"A lot of the companies working in molecular diagnostics don't have a good approach to telling physicians what to do and helping out with decision making. Quantgene has come to understand that that aspect of integrating clinical information and then providing guidance on what to do based on probabilities is helpful and necessary," said Jorge Nieva, an advisor to the company and an oncologist and associate professor at the University of Southern California Keck School of Medicine. "It has the real potential to revolutionize the field of cancer screening because our approach to cancer screening up to this point has really been organ-based." </p><p>What distinguishes the company, he said, is they are largely driven by math instead of biology. </p><p>"With the large database that Quantgene has built of some 40,000 tumors across 15 different cancers types, you can begin to build those patterns so that you can map those genetic abnormalities back to the anatomy," Nieva said. </p>From Your Site Articles
- The COVID-19 Crisis is Creating a New Biotech Culture in L.A. - dot.LA ›
- Wavemaker 360 Health Announces $100 Million Fund Aimed at ... ›
- Can LA County's New Fund Get Local Biotech Startups to Stick ... ›
- Quantgene Uses Big Data to Detect Cancer Earlier - dot.LA ›
- Quantgene Uses Big Data to Detect Cancer Earlier - dot.LA ›
- The New Tech at Dodger Stadium - dot.LA ›
- A LinkedIn For Esports - dot.LA ›
Related Articles Around the Web
Read more
Show less